Invokana

Invokana, also known as canagliflozin, is used along with diet and exercise to help adults with type-2 diabetes control their blood-sugar levels. When it was approved in March 2013, Invokana was the first drug in a new class of diabetes medications that work by helping the kidneys excrete excess sugar in urine.

Invokana is a type of drug known as a sodium-glucose cotransporter-2 (SGLT2) inhibitor. In May 2015, the FDA issued a Safety Communication for all SGLT2 inhibitors after receiving 20 reports of diabetic ketoacidosis in patients on these medications.
Diabetic ketoacidosis is a serious medical condition that occurs when cells in the body cannot get enough of the sugar they need to function. Instead, the body starts breaking down fat and muscle cells, which releases fatty acids known as ketones into the bloodstream. Left untreated, diabetic ketoacidosis can cause loss of consciousness, heart attack, kidney failure, cerebral edema, and even death.